USPSTF Advises Annual Low-Dose CT Lung Screening for High-Risk Individuals
Annual CT screening recommended for those aged 50 to 80 years at high risk due to smoking history.
Lung Cancer
New Drug Product: Tabrecta
This slideshow shows drug information for Tabrecta. Click here for the complete Tabrecta monograph.
FDA Approves Keytruda for Tumor Mutational Burden-High Cancer
The accelerated approval was based on data from a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic solid tumors with TMB-H who were enrolled in the open-label phase 2 KEYNOTE-158 trial.
Zepzelca Approved for Metastatic Small Cell Lung Cancer
The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Cyramza Plus Erlotinib Approved for First-Line Metastatic NSCLC With EGFR Mutations
The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Opdivo Plus Yervoy With Limited Chemotherapy Approved for First-Line Metastatic or Recurrent NSCLC
The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
New Drug Product: Retevmo
This slideshow shows drug information for Retevmo. Click here for the complete Retevmo monograph.
Alunbrig Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC
The FDA has approved Alunbrig® (brigatinib; Takeda) as a first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Lower Calculated Lung Cancer Risk in Black Patients Eligible for Screening
Compared with white patients, black patients with screen-detected cancers had a lower calculated lung cancer risk, despite having a significantly higher mean 6-year lung cancer risk.
Tecentriq Gains Approval for Additional Lung Cancer Indication
The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.
